171 results about "Methicillin resistant Staphylococcus" patented technology

The invention discloses an antibacterial peptide as well as a preparation method and application thereof. The antibacterial peptide has an amino acid sequence as shown in any one of SEQ ID NO: 1-11. The antibacterial peptide prepared by the scheme provided by the invention has very strong bacteriostasis and sterilization capabilities on methicillin-resistant staphylococcus aureus and multidrug-resistant escherichia coli, has application potential of becoming an antibacterial agent, a preservative or a disinfectant, and is not easy to generate drug resistance.

The invention discloses application of swertiflavin in preparation of a medicine for treating infectious pneumonia caused by methicillin-resistant staphylococcus aureus, and relates to the technical field of medicine. It is found for the first time that swertiflavin can significantly reduce the toxicity of staphylococcus aureus by inhibiting the activity of ClpP protein in MRSA. In addition, the swertiflavin shows a remarkable protection effect in the treatment of the MRSA infectious pneumonia. Specifically, the swertiflavin not only can relieve the injury degree of lung tissues, but also can reduce infiltration and aggregation of inflammatory cells in the lung. The discovery shows that the swertiflavin has potential application value in the field of anti-infection treatment. The invention provides a novel treatment strategy, namely, swertiflavin is used as an active ingredient for preparing the medicine for treating the staphylococcus aureus infectious pneumonia.

The invention relates to an antibacterial peptide and application thereof. The amino acid sequence of the antibacterial peptide is as shown in SEQ ID No. 1. The antibacterial peptide has excellent broad-spectrum antibacterial activity, for example, the antibacterial peptide has antibacterial activity on bacteria of the genus Staphylococcus (Staphylococcus), the genus Acinetobacter (Acinetobacter) and the genus Bacillus (Bacillus). Under the background that the global bacterial drug resistance problem is increasingly severe and traditional antibiotics gradually lose efficacy on multi-drug-resistant bacteria, a new treatment means is provided for treating bacteria such as methicillin-resistant staphylococcus aureus, carbapenem-resistant acinetobacter baumannii and bacillus subtilis which bring huge threats to public health. And a new possibility is provided for solving the problem that no medicine can be used clinically.

The invention provides a bridged triphenylamine-derived AIE type antibacterial photosensitizer, a preparation method and antibacterial application thereof, the bridged triphenylamine-derived AIE type antibacterial photosensitizer has the following structure: # imgabs0 is subjected to a cyclization reaction to form a bridged structure to limit bond rotation as a novel molecular design, and the photodynamic antibacterial effect of the AIE photosensitizer (PSs) can be effectively improved; and an AIE photosensitizer is combined with a donor-pi-receptor (D-pi-A) structure, so that a smaller singlet-triplet energy level difference (delta EST) is realized, and an intersystem crossing process is promoted. The mutual combination effect of the PSs and bacteria can be influenced by regulating and controlling the charge number of the PSs, so that effective bacteria recognition and selective antibacterial performance are realized. Experiments show that the AIE antibacterial photosensitizer based on bridged triphenylamine has a specific elimination effect on gram-positive bacteria; and the photodynamic antibacterial agent has a good photodynamic antibacterial effect on staphylococcus aureus and methicillin-resistant staphylococcus aureus.

The invention discloses a polyketone compound derived from actinomycetes as well as a preparation method and application thereof, and relates to the technical field of microbial natural product mining and biological medicine, and the key point of the technical scheme is that the invention discloses a novel polyketone compound Strepactone derived from actinomycetes Streptomyces sp. DP0001, and the molecular formula of the novel polyketone compound Strepactone is C25H38O5. The compound is obtained through strain fermentation, ethyl acetate extraction and multi-step chromatographic purification, and the structure is identified through ESI-MS, 1H NMR and 13C NMR. Experiments show that Strepactone has an inhibition effect on staphylococcus aureus and methicillin-resistant staphylococcus aureus and has remarkable inhibition activity on human non-small cell lung cancer A549 cells, the half inhibitory concentration IC50 of the Strepactone is 5.36 mu M, and the Strepactone has no obvious cytotoxic activity on human embryo kidney cells 293T cells at the concentration of 30 mu M. The compound provided by the invention can be used for preparing anti-drug-resistant bacteria drugs and anti-human non-small cell lung cancer drugs, and also provides a structural basis for the development of novel antibacterial and anti-tumor leading drugs.

The invention discloses a co-culture method of methicillin-resistant staphylococcus aureus and pseudomonas aeruginosa, and relates to the technical field of microbiology. Comprising the following steps: preparing materials: preparing methicillin-resistant staphylococcus aureus MRSA, pseudomonas aeruginosa PA and a culture medium; performing strain culture and activation, inoculating MRSA and PA, and performing subculture; preparing a bacterial suspension, and culturing MRSA and PA overnight; adding overnight culture bacterium liquid MRSA and PA into the culture medium, oscillating and uniformly mixing to prepare a bacterium suspension, and diluting for later use; the complete processes of strain preparation, bacterial suspension preparation, direct contact and indirect contact co-culture, drug sensitivity testing and the like are covered, and the interaction between MRSA and PA can be comprehensively researched; indirect contact co-culture is realized by adopting a Transwell insert, and a new method is provided for researching the interaction of two bacteria under the non-direct contact condition.

Described herein are Staphylococcal toxins inspired peptides (STIPs) with antimicrobial activity, compositions and kits comprising the peptides, and use of the peptides to treat microbial infections. Also described are methods of inhibiting or preventing the growth of a microorganism, and methods of treating microbial infections such as bacterial infections including MRSA, and fungal infections including C. albicans.

This invention discloses the application of ferrous ions in the preparation of products for treating bacterial infections, belonging to the field of pharmaceutical technology. Antibacterial activity tests of ferrous ions against Staphylococcus aureus showed strong bactericidal effects, with a survival rate of less than 0.001% against Staphylococcus aureus and less than 0.01% against methicillin-resistant Staphylococcus aureus (MRSA). The use of ferrous ion-containing hydrogels in the treatment of keratitis and skin wound infections significantly reduced the risk of MRSA infection in the lungs and effectively prevented the proliferation and spread of microorganisms in the body, revealing that drugs containing ferrous compounds can be used to treat Staphylococcus aureus infections, including MRSA.

This invention discloses a method for preparing and applying a photothermal nanoreagent targeting bacteria. This invention utilizes Ti3C2T... x Using MXene as a matrix, a photothermal nanoreagent MXene@PDA@Peptide (MPP) was constructed by sequentially modifying the surface of Ti3C2Tx MXene with polydopamine and grafting it with the peptide CAEKA, which has the function of recognizing bacteria. Under the recognition of the peptide CAEKA, the photothermal Ti3C2Tx MXene was targeted. x MXene nanosheets are guided to the surface of bacterial cells, achieving effective sterilization at a relatively low overall temperature of around 50°C (or achieving more efficient sterilization at the same overall temperature level, exhibiting superior sterilization performance compared to pure Ti3C2Tx MXene). This makes them particularly suitable for the preparation of therapeutic drugs for subcutaneous abscesses caused by methicillin-resistant Staphylococcus aureus (MRSA) infection.

The application belongs to the field of antibacterial two-dimensional nanomaterial Mxene catalysts, and particularly relates to a monolayer W@MoS2 nanosheet as well as a preparation method and application thereof. The method comprises the following steps: 1) dissolving water-soluble molybdate and water-soluble tungstate in water to obtain a mixed solution; 2) adding a sulfur source and an organic solvent to the mixed solution, and then performing reaction after mixing, and drying to obtain a powder. The monolayer W@MoS2 nanosheet has a unique two-dimensional planar structure, a large specific surface area, and good optical and electronic properties, and has high light-heat absorption in the near-infrared two region, i.e., the light-heat conversion efficiency is improved. Meanwhile, the peroxidase-like activity of the monolayer W@MoS2 nanosheet material realizes efficient light-heat amplification, can treat methicillin-resistant Staphylococcus aureus infection, and avoids heat therapy damage to normal tissues.

The invention belongs to the technical field of natural antibacterial drugs, and discloses application of cyclovirobuxine D and pharmaceutically acceptable salts thereof in preparation of antibacterial drugs. The invention discloses the effect of cyclovirobuxine D in preparation of antibacterial drugs, and tests prove that cyclovirobuxine D has remarkable antibacterial activity in inhibition of gram-positive bacteria such as staphylococcus aureus, gram-negative bacteria such as escherichia coli and super drug-resistant bacteria such as MRSA (Methicillin Resistant Staphylococcus Aureus).

The invention discloses a method for rapidly and efficiently preparing a series of novel ester group facaplysin derivatives by combining EDCI and HOBT to react with carboxyl facaplysin and directly carrying out ester exchange reaction on an active ester intermediate and alcohol without separation. The invention also discloses application of the derivatives in resisting methicillin-resistant staphylococcus aureus and escherichia coli. The preparation method comprises the following steps that EDCI and HOBT are combined to activate carboxyl facaplysin for reaction, an activated ester intermediate is generated, the activated ester intermediate and alcohol are directly subjected to esterification reaction without separation, and a series of ester-based facaplysin derivatives are obtained. According to the preparation method, ester-based Fascaplysin derivatives with different structures can be rapidly and efficiently constructed, and compared with a traditional method that ester-based carboline derivatives are firstly synthesized and then high-temperature intramolecular cyclization is performed, the time and the raw material cost are greatly saved, the synthesis efficiency is improved, the reaction process is observable and controllable, and the yield is stable. And the synthesized ester group facaplysin derivative has excellent antibacterial activity on methicillin-resistant staphylococcus aureus and escherichia coli.

The present invention relates to the technical field of pharmaceutical compounds and specifically discloses a selenocyanine pregnenol ketamide compound having the following general structural formula: #imgabs0#. The selenocyanine pregnenol ketamide compound of the present invention exhibits strong inhibitory activity against human breast cancer cells, cervical cancer cells, ovarian cancer cells, and human liver cancer cells. Furthermore, the selenocyanine pregnenol ketamide compound of the present invention also exhibits strong inhibitory effects against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE). The selenocyanine pregnenol ketamide compound of the present invention has low toxicity to humans and exhibits strong inhibitory effects against cancer cells and various drug-resistant bacteria at low concentrations. It can be used to prepare cancer treatment drugs and as an antibacterial agent against drug-resistant bacteria.

The application belongs to the technical field of medical materials, and particularly relates to a sonodynamic Ag2O / MoS2 nanocomposite material as well as a preparation method and application thereof. The Ag2O / MoS2 nanocomposite material is prepared by depositing Ag2O on the surface of MoS2 to construct a heterostructure under the catalysis of a surfactant CTAB. The inhibition rate of the Ag2O / MoS2 nanocomposite material prepared by the application to 10 6 CFU / mL of Staphylococcus aureus, Escherichia coli and methicillin-resistant Staphylococcus aureus reaches 95.98% or more.

The invention discloses a photoresponsive antibacterial hydrogel, which comprises a photosensitizer, acrylamide, potassium 3-sulfopropyl methacrylate, chitosan quaternary ammonium salt, an additive and a cross-linking agent, and the structure of the photosensitizer (PD-Se) is shown in the specification. A photosensitizer (PD-Se) is added into hydrogel, the positive charge characteristic of QSA hydrogel remarkably improves the local enrichment concentration of PD-Se in thalli by enhancing the binding force with the bacterial surface, unsaturated fatty acid in a bacterial membrane lipid bimolecular layer is oxidized after photoinduced ROS is generated, guanine bases in a DNA double-helix structure are attacked at the same time, and therefore the bioactivity of the bacterial membrane lipid bimolecular layer is improved. The gel is endowed with photodynamic antibacterial ability, has an excellent sterilizing effect on escherichia coli, staphylococcus aureus and methicillin-resistant staphylococcus aureus, and can be used for preparing hydrogel dressing for wound repair.

The invention belongs to the technical field of medicines, and relates to application of an indole-3-aryl ketone derivative to preparation of a medicine for treating or preventing infectious diseases caused by staphylococcus aureus, in particular to application of the indole-3-aryl ketone derivative to preparation of a medicine for treating or preventing infectious diseases caused by drug-resistant staphylococcus aureus. The chemical structural formula of the indole-3-aryl ketone derivative disclosed by the invention is as shown in a formula I shown in the specification. Results of the invention show that the compound I (namely the indole-3-aryl ketone derivative as shown in the formula I) has strong inhibitory activity on methicillin-resistant staphylococcus aureus ATCC43300, the inhibitory effect is dependent on concentration gradient, the MIC50 value is 27.45 mu g / mL, and the MIC50 value of a positive drug streptomycin sulfate is greater than 200 mu g / mL. Therefore, the indole-3-aryl ketone derivative can be used for treating or preventing infectious diseases caused by the staphylococcus aureus.

Naphthoquinone derivatives of Lawsone have been found to be effective against Staphylococcus aureus and methicillin resistant Staphylococcus aureus (MRSA). Such compounds generally contain a substituent group at the 3-position of a specific naphthoquinone compound, i.e. 2-hydroxy-1,4-naphthoquinone. One of these derivatives referred to as compound 6c in the series exhibits potent antimicrobial activity that is comparable to that of the two commercial antibiotics ofloxacin and ciprofloxacin against the two strains of methicillin sensitive Staphylococcus aureus (MSSA; ATCC 29213 and ATCC 6538). In the case of two strains of MRSA (ATCC BAA-44 and ATCC BAA-1717) that have developed drug resistance to both ofloxacin and ciprofloxacin, the antimicrobial activity of 6c can almost rival that of vancomycin and daptomycin. Furthermore, 6c is also effective against vancomycin-intermediate and daptomycin non-susceptible strain of MRSA (ATCC 700699). Besides the efficacy, 6c has a much improved drug resistance profile in comparison with the conventional antibiotics.

The invention provides an antibacterial active peptide YC18 and antibacterial application, and belongs to the technical field of biological medicine. The invention provides an antibacterial peptide. The amino acid sequence of the antibacterial peptide is as shown in SEQ ID No. 1. The active polypeptide YC18 has different degrees of antibacterial activity to various bacteria, especially has MIC of 6.25 mu g / ml to staphylococcus aureus and methicillin-resistant staphylococcus aureus, and is good in antibacterial effect and high in sterilization speed. The active polypeptide YC18 has the capacity of inhibiting and removing a biofilm, is low in hemolytic activity and free of cytotoxicity, does not easily generate drug resistance in the use process, has an obvious protection effect on an abdominal cavity infection model, and has the potential of being applied as an anti-infection drug.

Composition for use for the treatment and / or prevention of infections or lesions of the (oral) mucosa, in particular originating from at least one selected the group consisting of: perleche; scarlet fever; pharyngitis; acute necrotising ulcerative mucositis; impetigo contagiosa; chelitis glandularis apostem atosa; gingivostomatitis herpetica; herpes simplex; herpes stabistis recidivans; herpes zoster; hand-foot-mouth; human papilloma virus; HIV; oral candidiasis; oral lichen planus; lichen ruber planus; leukoplakia, erythroplakia; methicillin-resistant staphylococcus aureus; gingivitis / periodontitis; mucositis / peri- implantitis; alveolar osteolytis; wherein the composition comprises or consists of the following components: (a) polyhexanide (PHMB); (b) an organic or inorganic buffer different from a); (c) further additives; (d) optionally water.

The invention provides an application of SX-682 in preparation of a drug for resisting staphylococcus aureus infection, and the SX-682 has a CAS number of 1648843-04-2. According to the technical scheme, the novel medical application of the SX-682 is disclosed, and the SX-682 has better antibacterial activity on staphylococcus aureus and can inhibit formation of biofilms including methicillin-sensitive staphylococcus aureus (MSSA) and methicillin-resistant staphylococcus aureus (MRSA). The SX-682 has no significant toxicity to human cytotoxicity in the bacteriostatic concentration range, and provides key support for subsequent anti-infection application of the SX-682.

The invention discloses application of iso-pasteuretin in preparation of a medicine for treating diseases caused by methicillin-resistant staphylococcus aureus, and belongs to the technical field of biological medicine. According to the present invention, it is identified that the snowfield tea endophytic fungus 202109-Ts-F016 is the new Coprinopsis thamnolicola under coprinus pseudoratus, three monomeric compounds with anti-MRSA activity are separated from the secondary metabolite of the Coprinopsis thamnolicola, the three compounds can be adopted as the candidate inhibitors of the novel antibacterial target FtsZ, and the toxicity of the pasteurestin C and the iso-pasteurestin on the Vero cell is low. The invention provides an important basis and a material basis for the development of coprinus fungus metabolites and anti-MRSA new target drugs.

This invention belongs to the field of biomedical functional materials technology, and relates to an antibacterial and healing-promoting photosensitizer, its preparation method, and its uses. The photosensitizer is a defective MIL-88B@MIL-88C composite material, wherein defective MIL-88B serves as the substrate, and MIL-88C grows on the surface and / or in the pores of the defective MIL-88B. This photosensitizer significantly improves the photogenerated carrier separation efficiency, reduces impedance, enhances photocurrent response, and can efficiently generate reactive oxygen species under light irradiation. Antibacterial experiments show that it has excellent bactericidal effects against Staphylococcus aureus, Escherichia coli, and methicillin-resistant Staphylococcus aureus, and is not prone to inducing drug resistance. Simultaneously, this photosensitizer has good biocompatibility, promotes cell migration, and has significant hemostatic function. Animal models show that it can effectively accelerate the healing of skin defects.

Provided are compositions for controlling the growth of methicillin-resistant Staphylococcus aureus (MRSA). Uses of the compositions, alone or in combination with certain other agents, are also disclosed.

The invention relates to the technical field of biology, in particular to a broad-spectrum bacteriophage lyase mutant, an extraction and purification reagent and a kit. The invention provides a broad-spectrum bacteriophage lyase mutant, an extraction and purification reagent and a kit. A broad-spectrum bacteriophage lyase mutant nucleic acid release liquid containing protein with an amino acid sequence as shown in SEQ ID NO: 1 is adopted; the compound can efficiently act on two important clinical drug-resistant bacteria, namely methicillin-resistant staphylococcus aureus MRSA and vancomycin-resistant enterococcus VRE, at the same time. Through unique molecular design and preparation process optimization, the lyase shows excellent synchronous wall breaking capacity, cell wall destruction can be completed in an extremely short time, and the nucleic acid release efficiency is remarkably superior to that of a traditional method.

The invention discloses a method for rapidly detecting methicillin-resistant staphylococcus aureus and application of the method. According to the invention, a loop-mediated isothermal amplification (LAMP) technology is combined with a naturally extracted luminescent molecule-berberine for rapid detection of methicillin-resistant staphylococcus aureus. The operation process is simple and convenient, the dependence on instruments and equipment can be reduced, the detection cost can be greatly reduced by the luminous Chinese herbal medicine, the result judgment is performed by directly observing the generated fluorescence signal, the visualization and intuition of the detection result are realized, and the operation and result judgment of non-professional personnel are facilitated.

The application discloses a kind of smelly danchang dots and preparation method and application, belong to medical technical field.The preparation method of smelly danchang dot includes: smelly danchang fine powder is dispersed in distilled water, and is stirred pyrolysis on heating table;Pyrolysis product is diluted with distilled water, and supernatant is obtained by centrifugation, filter membrane filtration, dialysis, freeze-drying, to obtain carbon dot.The average particle size of obtained carbon dot is 4.51±1.04nm.The smelly danchang dot prepared in the application shows strong inhibitory activity to a variety of gram-positive bacteria (such as listeria, methicillin-resistant staphylococcus aureus MRSA) and fungi (such as Candida albicans), especially to clinically tricky drug-resistant strains, such as vancomycin-resistant enterococci (VRE) and MRSA effective, can be applied to the preparation of antibacterial drugs, antibacterial dressing, disinfectant or preservative, with the advantages of wide raw material source, simple preparation method, low cost, environment-friendly and the like.

This invention discloses the application of the bacterial fission protein FtsZ inhibitor DB1 in the preparation of drugs against drug-resistant bacteria, belonging to the field of drug development technology. The inhibitor provided by this invention is compound DB1, named 3-(2,8-dibromo-10,11-dihydro-5H-dibenzo[b,f]azapheno-5-yl)-N,N-dimethylpropylamine hydrochloride, with the molecular formula C2. 19 H 24 Br2ClN2. This compound, DB1, exhibits significant inhibitory effects against various drug-resistant bacteria, particularly vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus (MRSA), and can significantly improve the susceptibility of methicillin to MRSA. The discovery of compound DB1 provides new ideas and technical support for the preparation of drugs against drug-resistant bacteria.

The thermoelectric material opens up a new way for self-power supply of microelectronic devices, and the combination with the sensor has been significantly developed. However, the application of the thermoelectric material in the field of biosensors is still challenged, which limits the potential of the thermoelectric material in exploring biochemical reactions and promoting the development of biosensors. The invention innovatively provides a detection method based on a silver selenide thermoelectric film, and efficient detection of hydrogen peroxide is realized through photo-thermal-thermoelectric conversion. Compared with a traditional method, the method is short in detection time, low in cost and easy and convenient to operate. Furthermore, the specific detection of streptococcus sanguis and methicillin-resistant staphylococcus aureus is realized by utilizing the characteristics of different bacteria, and a new guiding thought is provided for the diagnosis and treatment of diseases.

The application discloses a series of evodiamine derivatives containing pyridine quaternary ammonium salt, a preparation method and antibacterial application thereof. The series of compounds are prepared by introducing a pyridine ring and then connecting with a chloroacetamide fragment based on a natural product evodiamine as a mother structure, so as to prepare a series of evodiamine derivatives containing pyridine quaternary ammonium salt, and the structural general formula is shown in the following formula (1). The series of compounds have strong in-vivo and in-vitro antibacterial activities on Staphylococcus aureus ATCC 29213 and clinically isolated Methicillin-resistant S. aureus (MRSA). The water solubility and antibacterial activity of the application are enhanced through further structure optimization, and the in-vivo and in-vitro toxicity, safe hemolytic activity and low drug resistance are low. Therefore, the evodiamine derivatives containing pyridine quaternary ammonium salt have the potential to be further developed as new antibacterial drugs.

Disclosed are compositions, methods, and systems for detecting MRSA, e.g., nasal colonization by MRSA. In certain embodiments, the methods use bacteriophage-based amplification of signals in the detection of bacteria and other microorganisms to detect MRSA. A method for detecting MRSA can include preparing an assay containing a selection agent and a cocktail containing at least two different types of recombinant bacteriophage, incubating a sample in the assay, capturing an indicator protein product, and detecting the indicator protein product produced by the recombinant bacteriophage, wherein positive detection of the indicator protein product indicates the presence of MRSA in the sample.